LifeStance Health Group (NASDAQ:LFST) Upgraded at KeyCorp

KeyCorp upgraded shares of LifeStance Health Group (NASDAQ:LFST) to a strong-buy rating in a research note released on Monday,Zacks.com reports.

LFST has been the topic of several other research reports. Canaccord Genuity Group began coverage on shares of LifeStance Health Group in a research report on Thursday, April 3rd. They issued a “buy” rating and a $8.00 price target on the stock. William Blair restated an “outperform” rating on shares of LifeStance Health Group in a report on Friday, February 28th. Finally, The Goldman Sachs Group raised LifeStance Health Group from a “neutral” rating to a “buy” rating and set a $10.00 target price on the stock in a research report on Monday, December 16th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $8.58.

LifeStance Health Group Stock Performance

Shares of LFST opened at $6.91 on Monday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.32 and a quick ratio of 1.32. The firm’s 50 day moving average is $7.33 and its 200-day moving average is $7.33. LifeStance Health Group has a 12-month low of $4.64 and a 12-month high of $8.61. The stock has a market capitalization of $2.66 billion, a P/E ratio of -26.58 and a beta of 1.30.

Insider Buying and Selling at LifeStance Health Group

In other LifeStance Health Group news, insider Lisa K. Miller sold 18,845 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $6.90, for a total transaction of $130,030.50. Following the completion of the sale, the insider now directly owns 339,810 shares in the company, valued at approximately $2,344,689. This trade represents a 5.25 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 6.60% of the company’s stock.

Institutional Trading of LifeStance Health Group

Hedge funds have recently made changes to their positions in the stock. Summit Global Investments purchased a new position in LifeStance Health Group during the first quarter valued at approximately $241,000. Wellington Management Group LLP boosted its stake in shares of LifeStance Health Group by 9.2% during the 4th quarter. Wellington Management Group LLP now owns 5,276,237 shares of the company’s stock valued at $38,886,000 after buying an additional 445,796 shares during the period. Forum Financial Management LP purchased a new position in shares of LifeStance Health Group during the 4th quarter valued at $110,000. Neo Ivy Capital Management increased its stake in shares of LifeStance Health Group by 26,132.3% in the fourth quarter. Neo Ivy Capital Management now owns 182,052 shares of the company’s stock worth $1,341,000 after acquiring an additional 181,358 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of LifeStance Health Group by 16.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 604,321 shares of the company’s stock worth $4,454,000 after acquiring an additional 87,502 shares in the last quarter. 85.50% of the stock is owned by hedge funds and other institutional investors.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.